Table 2 Indirect Work Steps: Average duration of each step and time worked by employee
Indirect Work Steps | n | Mean Time (min) |
|---|---|---|
(95% Confidence Interval) | ||
Physician Visits | ||
Exam room preparation and cleanup (orderly) | 27 | 1.1 (1.0 - 1.2) |
Sending tubes of blood down to laboratory (phlebotomist) | 10 | 1.0 (0.8 - 1.2) |
Retrieving and filing patient charts (clerk) | 300 | 0.6 (0.6 - 0.7) |
Total mean time worked by employees | 2.7 (2.3 - 3.1) | |
Treatment Visits | ||
FOLFOX (n=52); XELOX (n=8) | ||
Sending tubes of blood down to laboratory (phlebotomist) a, b | 10 | 1.0 (0.8 - 1.2) |
Retrieving and filing patient charts (clerk) a, b | 300 | 0.6 (0.6 - 0.7) |
Prescription validation (pharmacist) a, b | 16 | 5.3 (4.0 - 6.5) |
Preparation of calcium and magnesium a, b | 44 | 6.5 (6.0 - 6.8) |
1. pharmacist | 44 | 2.8 (2.8 - 2.8) |
2. pharmacy technician | 44 | 3.7 (3.3 - 4.0) |
Preparation of FOLFOX (5-FU, leucovorin, oxaliplatin) a | 6 | 39.6 (35.9 - 43.3) |
1. pharmacist | 6 | 18.6 (14.5 - 22.7) |
2. pharmacy technician | 6 | 21.0 (16.7 - 25.2) |
Pre-counts of capecitabine and labeling (pharmacy technician) b | 10 | 2.0 (2.0 - 2.0) |
Preparation of capecitabine tablets for XELOX treatment b | 6 | 3.4 (2.3 - 4.5) |
1. pharmacist | 6 | 0.5 (0.2 - 0.8) |
2. pharmacy technician | 6 | 2.9 (2.1 - 3.7) |
Preparation of oxaliplatin for XELOX treatment b | 9 | 7.9 (7.2 - 8.5) |
1. pharmacist | 9 | 3.9 (3.4 - 4.4) |
2. pharmacy technician | 9 | 4.0 (3.5 - 4.4) |
Preparation of bevacizumab a, b | 6 | 10.1 (8.4 - 11.8) |
1. pharmacist | 6 | 4.9 (3.8 - 6.0) |
2. pharmacy technician | 6 | 5.2 (3.6 - 6.9) |
Prescription/treatment verification (nurse) a, b | 14 | 4.5 (−0.8 - 9.8) |
Preparation and verification of IV bags, premeds (nurse) a, b | 54 | 2.4 (1.9 - 3.0) |
Total mean time worked by employees (all indirect steps) (Based on 86.7% FOLFOX/bevacizumab – n=52; 13.3% XELOX/bevacizumab – n=8) | 66.5 (59.6 - 73.2) | |
Total mean time worked by employees | ||
1. FOLFOX/bevacizumab treatment a | 70.0 (67.1 - 72.7) | |
2. XELOX/bevacizumab treatment b | 43.7 (41.2 - 46.0) |